Prematür ejakülasyonda güncel tedavi yaklaşımları

Fatih Gokalp; Mutlu Deger; Volkan İzol

Review

Prematür ejakülasyonda güncel tedavi yaklaşımları

Year 2018, Volume: 1 Issue: 1, 10 - 13, 31.12.2018

Fatih Gokalp , Mutlu Deger , Volkan İzol

Abstract

ÖZET

Prematür ejakülasyon (PE) erkek cinsel sağlığında en sık karşılaşılan ve hayat kalitesini önemli derecede etkileyen bir hastalıktır. Patofizylojisinin net olarak anlaşılmaması tanı ve tedavi güçlüğüne neden olmaktadır. Bu eksikliklere rağmen hekimler, hastalarını kılavuzlara göre PE ile teşhis etmeye ve bunlara davranış terapileri veya etiket dışı ilaçlarla tedavi etmeye devam ediyorlar. Tedavinin temelini topikal anestezikler ve seçici seratonin geri alım inhibitörleri oluşturmaktadır. Dapoksetin de güçlü bir seçici seratonin geri alım inhibitörü olmasına rağmen tedavisinde isteğe bağlı kullanım için dizayn edilmiştir. Bu derlemede, PE tedavisindeki özellikle güncel yaklaşımlar literatür eşliğinde tartışılmıştır.

Keywords

Prematür ejakülasyon, Güncel tedaviler, SSGİ, Topikal anestezikler, Dapoksetin

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-DSM III. 3rd edition. Washington DC: APA; 1980.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-DSM IV-TR. 4th edition revised. Washington DC: APA; 2000.
3. Masciovecchio S, Saldutto P, Del Rosso A, et al. The daily therapy with silodosin can have a role in the treatment of ‘life long’ premature ejaculation. J Androl Sci. 2011;18: 48-51.
4. Balcı M, Aslan Y, Aydın AÖ ve ark. Türk erkeklerinde cinsel fonksiyon bozukluğu taraması: Anket çalışması. Ortadoğu Tıp Dergisi. 2009;4:108-13.
5. Theodore Robert Saitz , Ege Can Serefoglu The epidemiology of premature ejaculation, Transl Androl Urol. 2016;5:409-15.
6. Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia. 2002;34:356-9.
7. Atan A, Basar MM, Tuncel A, et al. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology. 2006;67:388–91.
8. McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride. Int J Impot Res. 1999;11:241-5.
9. Atmaca M, Kuloglu M, Tezcan E, et al. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002;14:502-5.
10. Kara H, Aydin S, Yücel M, et al. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol. 1996;156:1631-2.
11. Althof SE, Levine SB, Corty EW, et al. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry. 1995;56:402-7.
12. McMahon CG. Premature ejaculation. Indian J Urol 2007;23:97-108.
13. Waldinger MD, Zwinderman AH, Olivier B. SSGİs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001;21:556–60.
14. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.
15. Tanrikut C, Feldman AS, Altemus M, et al. Adverse effect of paroxetine on sperm. Fertil Steril. 2010;94:1021-6.
16. Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol. 2004;46:510-5.
17. McMahon CG, Althof SE, Kaufman JM, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2011;8:524-39.
18. Safarinejad MR. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol. 2006;29:243-52.
19. Levine L. Evaluation of withdrawal effects with dapoxetine in the treatment of premature ejaculation (PE). Poster presented at the meeting of SMSNA, 2006.
20. Sun Y, Luo D, Yang L, et al. Efficacy of Phosphodiesterase-5 Inhibitor in Men With Premature Ejaculation: A New Systematic Review and Meta-analysis. Urology. 2015;86:947-54.
21. Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014;11:1392-422.
22. Martyn-St James M, Cooper K, Kaltenthaler E, et al. Tramadol for premature ejaculation: a systematic review and meta-analysis. BMC Urol. 2015;15:6-13.
23. Waldinger MD, Zwinderman AH, Schweitzer DH, et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta analysis. Int J ImpotRes. 2004;16:369-81. 24. Başar MM, Yilmaz E, Ferhat M, et al. Terazosin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol. 2005;37:773-7.
25. Bhat GS, Shastry A. Effectiveness of ‘on demand’ silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study. Cent European J Urol. 2016; 69: 280-4.

Year 2018, Volume: 1 Issue: 1, 10 - 13, 31.12.2018

Fatih Gokalp , Mutlu Deger , Volkan İzol

Abstract

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-DSM III. 3rd edition. Washington DC: APA; 1980.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-DSM IV-TR. 4th edition revised. Washington DC: APA; 2000.
3. Masciovecchio S, Saldutto P, Del Rosso A, et al. The daily therapy with silodosin can have a role in the treatment of ‘life long’ premature ejaculation. J Androl Sci. 2011;18: 48-51.
4. Balcı M, Aslan Y, Aydın AÖ ve ark. Türk erkeklerinde cinsel fonksiyon bozukluğu taraması: Anket çalışması. Ortadoğu Tıp Dergisi. 2009;4:108-13.
5. Theodore Robert Saitz , Ege Can Serefoglu The epidemiology of premature ejaculation, Transl Androl Urol. 2016;5:409-15.
6. Atikeler MK, Gecit I, Senol FA. Optimum usage of prilocaine-lidocaine cream in premature ejaculation. Andrologia. 2002;34:356-9.
7. Atan A, Basar MM, Tuncel A, et al. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology. 2006;67:388–91.
8. McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride. Int J Impot Res. 1999;11:241-5.
9. Atmaca M, Kuloglu M, Tezcan E, et al. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002;14:502-5.
10. Kara H, Aydin S, Yücel M, et al. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol. 1996;156:1631-2.
11. Althof SE, Levine SB, Corty EW, et al. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry. 1995;56:402-7.
12. McMahon CG. Premature ejaculation. Indian J Urol 2007;23:97-108.
13. Waldinger MD, Zwinderman AH, Olivier B. SSGİs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001;21:556–60.
14. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.
15. Tanrikut C, Feldman AS, Altemus M, et al. Adverse effect of paroxetine on sperm. Fertil Steril. 2010;94:1021-6.
16. Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol. 2004;46:510-5.
17. McMahon CG, Althof SE, Kaufman JM, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2011;8:524-39.
18. Safarinejad MR. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol. 2006;29:243-52.
19. Levine L. Evaluation of withdrawal effects with dapoxetine in the treatment of premature ejaculation (PE). Poster presented at the meeting of SMSNA, 2006.
20. Sun Y, Luo D, Yang L, et al. Efficacy of Phosphodiesterase-5 Inhibitor in Men With Premature Ejaculation: A New Systematic Review and Meta-analysis. Urology. 2015;86:947-54.
21. Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014;11:1392-422.
22. Martyn-St James M, Cooper K, Kaltenthaler E, et al. Tramadol for premature ejaculation: a systematic review and meta-analysis. BMC Urol. 2015;15:6-13.
23. Waldinger MD, Zwinderman AH, Schweitzer DH, et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta analysis. Int J ImpotRes. 2004;16:369-81. 24. Başar MM, Yilmaz E, Ferhat M, et al. Terazosin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol. 2005;37:773-7.
25. Bhat GS, Shastry A. Effectiveness of ‘on demand’ silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study. Cent European J Urol. 2016; 69: 280-4.

There are 24 citations in total.

Details

Primary Language	Turkish
Subjects	Surgery
Journal Section	Reviews
Authors	Fatih Gokalp 0000-0003-3099-3317 Mutlu Deger Volkan İzol
Publication Date	December 31, 2018
Acceptance Date	December 27, 2018
Published in Issue	Year 2018 Volume: 1 Issue: 1

Cite

APA	Gokalp, F., Deger, M., & İzol, V. (2018). Prematür ejakülasyonda güncel tedavi yaklaşımları. Journal of Cukurova Anesthesia and Surgical Sciences, 1(1), 10-13.

Download Cover Image

Article Files

Full Text

download

You are free to:

Share — copy and redistribute the material in any medium or format The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. NonCommercial — You may not use the material for commercial purposes. NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.